Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Postpartum Hemorrhage Treatment Market: By Drug Type, Ergot Alkaloids, Tranexamic acid, Pabal, Carboprost, Others), By Route of Administration, By Distribution Channel and Region Forecast 2019-2030
Postpartum hemorrhage treatment market size was valued at US$ 962.34 million in 2023, growing at a CAGR of 5.3% during the forecast period 2024-2030. The Postpartum Hemorrhage (PPH) is an obstetric hemorrhagic condition that is a prime reason for maternal mortality. In postpartum hemorrhagic condition patient loss about 500mL blood in vaginal delivery or approximately 1000mL blood after cesarean delivery. It is categorized into two types namely, primary postpartum hemorrhage and secondary postpartum hemorrhage. Most commonly used drugs in postpartum hemorrhage are oxytocin and misoprostol.
Rise in prevalence of multiple pregnancies, inverted uterus, and other pregnancy complication, increase in risk factors for postpartum hemorrhage such as uterine atony, rise in R&D for the innovation of newer drugs, product pipeline of postpartum hemorrhage drugs, and rise in anemia in pregnant woman are anticipated to fuel the postpartum hemorrhage treatment market. However, adverse effects associated with drugs, stringent regulatory guidelines for newer drug approval, and lack of awareness about drugs in underdeveloped countries may impede the growth of postpartum hemorrhage treatment market.
Study Period
2024-2030Base Year
2023CAGR
5.3%Largest Market
EuropeFastest Growing Market
North America
Increasing pregnancy problems like inverted uterus, big size of the baby and multiple pregnancies are some key drivers of the market growth. Technological development like capability of the devices to soothe the patients condition until permanent treatment is given is propelling the market growth. The Support from healthcare organizations, Rising pregnancy complications. Dearth of trained healthcare providers, High cost of the devices.
Report Benchmarks |
Details |
Report Study Period |
2024-2030 |
Market Size in 2023 |
US$ 962.34 million |
Market CAGR |
5.3% |
By Drug Type |
|
By Route Administration |
|
By Distribution Channel |
|
By Region |
|
Download Free Sample Report
The global postpartum hemorrhage treatment market size was valued at US$ 962.34 million in 2023 and is projected to grow at a CAGR of 5.3%
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The postpartum hemorrhage treatment market key players are Novartis AG, Fresenius Kabi AG, Pfizer, Inc., GlaxoSmithKline Plc, Ferring B.V., Cipla Inc.
1. Executive Summary |
2. Global Postpartum Hemorrhage Treatment Market Introduction |
2.1.Global Postpartum Hemorrhage Treatment Market - Taxonomy |
2.2.Global Postpartum Hemorrhage Treatment Market - Definitions |
2.2.1.Drug Type |
2.2.2.Route Administration |
2.2.3.Distribution Channel |
2.2.4.Region |
3. Global Postpartum Hemorrhage Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4. Global Postpartum Hemorrhage Treatment Market Analysis, 2019- -2030 and Forecast 2024 - 2030 |
4.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5. Global Postpartum Hemorrhage Treatment Market By Drug Type, 2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
5.1. Oxytocin |
5.1.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Prostaglandins (Dinoprostone, Misoprostol) |
5.2.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
5.3.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Tranexamic acid |
5.4.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Pabal |
5.5.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Carboprost |
5.6.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
5.7. Others |
5.7.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.7.3. Market Opportunity Analysis |
6. Global Postpartum Hemorrhage Treatment Market By Route Administration, 2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
6.1. Oral |
6.1.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Parenteral |
6.2.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
7. Global Postpartum Hemorrhage Treatment Market By Distribution Channel, 2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
7.1. Hospital Pharmacies |
7.1.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacies |
7.2.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacies |
7.3.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8. Global Postpartum Hemorrhage Treatment Market By Region, 2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2019- -2030 and Forecast, 2024 - 2030, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9. North America Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
9.1. Drug Type Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Oxytocin |
9.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
9.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
9.1.4.Tranexamic acid |
9.1.5.Pabal |
9.1.6.Carboprost |
9.1.7.Others |
9.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Oral |
9.2.2.Parenteral |
9.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacies |
9.3.2.Retail Pharmacies |
9.3.3.Online Pharmacies |
9.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10. Europe Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
10.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Oxytocin |
10.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
10.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
10.1.4.Tranexamic acid |
10.1.5.Pabal |
10.1.6.Carboprost |
10.1.7.Others |
10.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Oral |
10.2.2.Parenteral |
10.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacies |
10.3.2.Retail Pharmacies |
10.3.3.Online Pharmacies |
10.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11. Asia Pacific (APAC) Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
11.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Oxytocin |
11.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
11.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
11.1.4.Tranexamic acid |
11.1.5.Pabal |
11.1.6.Carboprost |
11.1.7.Others |
11.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Oral |
11.2.2.Parenteral |
11.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacies |
11.3.2.Retail Pharmacies |
11.3.3.Online Pharmacies |
11.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12. Middle East and Africa (MEA) Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
12.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Oxytocin |
12.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
12.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
12.1.4.Tranexamic acid |
12.1.5.Pabal |
12.1.6.Carboprost |
12.1.7.Others |
12.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Oral |
12.2.2.Parenteral |
12.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacies |
12.3.2.Retail Pharmacies |
12.3.3.Online Pharmacies |
12.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13. Latin America Postpartum Hemorrhage Treatment Market ,2019- -2030 and Forecast 2024 - 2030 (Sales Value USD Million) |
13.1. Drug Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Oxytocin |
13.1.2.Prostaglandins (Dinoprostone, Misoprostol) |
13.1.3.Ergot Alkaloids (Ergometrine, Methyl Ergonovine) |
13.1.4.Tranexamic acid |
13.1.5.Pabal |
13.1.6.Carboprost |
13.1.7.Others |
13.2. Route Administration Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Oral |
13.2.2.Parenteral |
13.3. Distribution Channel Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacies |
13.3.2.Retail Pharmacies |
13.3.3.Online Pharmacies |
13.4. Country Analysis 2019- -2030 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Novartis AG (Switzerland) |
14.2.2.Fresenius Kabi AG (Germany) |
14.2.3.Pfizer, Inc. (U.S.) |
14.2.4.GlaxoSmithKline Plc (U.K.) |
14.2.5.Ferring B.V. (Switzerland) |
14.2.6.Cipla Inc. (India) |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players